57results about How to "Long-lasting immunity" patented technology

The present invention belong to veterinary new biological medicine technology field, relates to porcine circovirus type II (PCV2) inactivated vaccine of and method for preparing same. The vaccine used seed virus is porcine circovirus type II DBN-SX07 strain, the preservation number is CGMCC No 3064, the virus strain is used as antigen preparation of inactivation by alkyl agents and emulsification by adding oil adjuvant. Using the invention provided PCV2 inactivated vaccine to immune pig can generate an uniform and effective protection force-shorting PCV2 infection windows period obviously, and prolong immune duration-reducing times of booster immunization.

Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, and chimeric antigen receptors (CARs) directed against the human FAP antigen as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.

The invention provides an adjuvant used for vaccine. The adjuvant comprises alumina gel, levamisole or its derivative, and also polyacrylate. The invention also discloses a vaccine composition containing the adjuvant and an application thereof. The adjuvant can be used as the adjuvant for inactivated vaccine, and also can be used for preparing protein stabilization liquid. The vaccine composition containing the adjuvant can generate humoral immunity for human body and can generate cellular immunity, and can generate good immune response under condition of low antigen content and single immune, and can stabilize protein, degradation and irreversible change cannot be generated.

Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.

The present invention relates to the field of veterinary biological products, and more specifically discloses a type-A foot-and-mouth disease virus-like particle and an anti-foot-and-mouth disease vaccine composition and a preparation method and application thereof in prevention and / or treatment of infections-related diseases caused by FMD (foot-and-mouth disease) virus. The vaccine composition comprises a type-O FMD virus-like particle and / or type-Asia-I FMD virus-like particle and / or the type-A FMD virus-like particle and an adjuvant.

The invention provides a bigeminy inactivated vaccine of porcine circovirus type 2 and swine mycoplasma pneumoniae and a preparation method of the bigeminy inactivated vaccine. The bigeminy inactivated vaccine comprises inactivated porcine circovirus type 2, inactivated swine mycoplasma pneumoniae, a vaccine adjuvant, and an excipient, wherein the content of the porcine circovirus type 2 is at least105.5 tissue culture inoculated dose (TCID) 50/head, and the content of the swine mycoplasma pneumoniae is at least 2*109 MHDCE/head. The bigeminy inactivated vaccine has the advantages that the immune effect is equal to or better than the effect of sum of commodity single vaccines in the market, two antigens do not interfere each other, immune persistent period is long, potency is lasting, and due to the fact that one time immunization only needs, cost is lowered, and stress reaction of animals is also reduced. The bigeminy inactivated vaccine can be used for preventing porcine circovirus disease and at the same time preventing the swine mycoplasma pneumoniae.

The present invention provides a construction method for specifically targeting the receptor protein MAGEA and its CAR-T carrier. The construction method includes first extracting the RNA of monoclonal hybridoma cells against osteosarcoma, and then using the specific monoclonal antibody RT-PCR with specific primers, clone the variable region DNA fragments of the heavy and light chains of the antibody into the T vector, sequence, obtain the receptor protein MAGEA that specifically recognizes tumor cells, and clone its expression sequence into CAR-T On the carrier, a new type of CAR‑T carrier specifically targeting MAGEA was obtained. The present invention can provide an effective target for solid tumors treated by CAR-T cells, especially in the immunotherapy of osteosarcoma.

The invention discloses a triple inactivated vaccine for newcastle disease, infectious bronchitis and H9 subtype avian influenza. The triple inactivated vaccine comprises inactivated newcastle disease virus La Sota strain, infectious bronchitis virus M41 strain and H9 subtype avian influenza virus SY strain; the preservation number of the H9 subtype avian influenza virus SY strain is CGMCC No. 5968. The triple inactivated vaccine for newcastle disease, infectious bronchitis and H9 subtype avian influenza is good in immune effect, and stable and reliable in preparation technology.

Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.

The invention relates to the technical field of veterinary biological products, in particular to a group I avian adenovirus type 8 strain and application thereof. The group I avian adenovirus type 8 strain ZMYTAV-8 strain, with an accession number of CGMCC No. 14297 has the characteristics of high toxin production and good immunogenicity. The strain can effectively prevent chicken inclusion body hepatitis caused by serum avian adenovirus type 8. Therefore, the invention also provides application of the avian adenovirus type 8 strain ZMYTAV-8 in the preparation of drugs for the prevention of inclusion body hepatitis. Further, the present invention provides a bivalent inactivated vaccine of avian adenovirus serotype 4, serotype 8 for the prevention of pericardial effusion-hepatitis syndromeand inclusion body hepatitis. The vaccine has good immunogenicity and can prevent avian diseases caused by adenovirus, such as inclusion body hepatitis and pericardial effusion-hepatitis syndrome, which are popular in recent years. The vaccine has 100% protection rate against local isolates, and has high safety, rapid antibody production and stable efficacy.

The invention provides a pseudorabies virus passage attenuated strain and an application thereof, and belongs to the field of vaccines of animal medicine. The pseudorabies virus passage attenuated strain is a pseudorabies virus LA2017 strain, and the preservation number is CGMCC No.18170. The invention also provides an application of the pseudorabies virus passage attenuated strain to preparationof pseudorabies vaccines, and a vaccine using the pseudorabies virus passage attenuated strain as an active component. The LA2017 strain is a natural deletion attenuated strain, the virulence is notably reduced, and when new-born piggies are inoculated with the LA2017 strain, no adverse reactions are caused. The strain is obtained by a passage attenuated method, so that the biological security risk is low. After weaned highly-susceptible piggies are subjected to primary inoculation of the vaccines prepared from the LA2017 strain for 7 days, 100% of protective effects can be achieved, and the immunization persistent period can achieve 5 months. The vaccines not only can prevent pathogenesis but also can prevent toxin expelling, and purification of pseudorabies virus variation strains can beextremely facilitated.

The invention discloses a nucleic acid and recombinant protein co-immune vaccine based on a classical swine fever virus gene as well as a preparation method and application of the co-immune vaccine. The preparation method comprises the steps that firstly, optimized recombinant plasmids and recombinant classical swine fever vaccine antigen protein are obtained by combining gene engineering and cellengineering; then the nucleic acid sequence and the recombinant protein are compounded into different liquid phase layers of a biphasic adjuvant, so that the obtained co-immune vaccine is good in immunogenicity and short in immune blank period, can rapidly induce an organism to generate high-level, high-affinity and durable antibody response and immune memory, effectively protects a target animalfrom being attacked by classical swine fever virulent viruses, and the method can be applied to preparation of products for preventing/treating classical swine fever.

The invention discloses a canine distemper virus attenuated vaccine strain and application thereof. The canine distemper virus is named as an HBa strain, and the microorganism has the preservation number of CGMCC No.15036. The separated canine distemper virus is subjected to passage and cloning on a Vero cell, the attenuated vaccine strain (HBa strain) is cultured, and the results of a pathogenicity test and an immunogenicity test show that the canine distemper virus HBa strain is not pathogenic to both minks or dogs and can provide quite good protecting force for other sources of strong poison attacks. The attenuated vaccine strain has good immunogenicity, can be prepared into a single vaccine or combined vaccine, can effectively prevent diseases caused by the canine distemper virus, andcan also be used for preparing reagents or kits for treating, diagnosing or detecting the diseases caused by the canine distemper virus. The attenuated vaccine strain has the advantages of being stable in hereditary, lasting in immune, good in effect, safe, reliable, long in storage life and the life.

The invention discloses an immunopotentiator for a swine atrophic rhinitis inactivated vaccine. The immunopotentiator comprises a liquid containing dry powder immunity particles, and a solvent, wherein the liquid containing the dry powder immunity particles mainly comprises an aluminium hydroxide aqueous solution, ginsenoside, cholesterol, a vitamin C, diethylaminoethyl glucan, potassium iodide and polyethylene glycol according to an appropriate ratio by compatibility. Compared with the prior art, the prepared immunopotentiator for the swine atrophic rhinitis inactivated vaccine can effectively inhibit establishment and reactivation of latent infection of bordetella bronchiseptica and pasteurella multocida, can shorten a window phase of antibody production, improves an immunity effect of the swine atrophic rhinitis vaccine, prolongs the immunity duration, effectively avoids latent infection of swine atrophic rhinitis, provides guarantee for prevention and elimination of the swine atrophic rhinitis, can be widely applied to a pig farm for prevention and treatment of the swine atrophic rhinitis, and increases an economic benefit of the pig farm.

The invention belongs to the technical field of veterinary biological products, and relates to a fast and efficient preparation method of a pig A type clostridium perfringens inactivated vaccine. Themethod comprises the following steps of picking a suspected sample of an A type clostridium perfringens lethal diseased pig, scraping an intestinal content, and refrigerating or freezing; autoclavinga culture medium in an autoclave, after temperature reducing, pouring the suspected sample in the autoclave, carrying out anaerobic culture, and carrying out passage for three times; inoculating bacteria liquid subjected to three-time passage into a meat liver-stomach membrane digestion soup, culturing, and centrifuging after finishing culturing, thus obtaining a supernatant liquor; adding an inactivator into the supernatant liquor, fully shaking out, inactivating, and detoxifying to obtain inactivated bacteria liquid; mixing the inactivated bacteria liquid and an adjuvant to obtain the inactivated vaccine. The method provided by the invention has the advantages of simple process, low cost, and low pollution; the prepared inactivated vaccine has the advantages of high safety, no adverse reaction after being injected, high immunization efficiency and long immunity period.

The invention discloses a preparation method of fructus momordicae health wine. The preparation method comprises the following steps: preparing fructus momordicae raw liquid; mixing the raw liquid andleaching liquid of maca, ginseng, burdock, medlar, jujubes, gecko tails, male silkworm moths and yam; mixing the mixed raw liquid, honey and crystal sugar, filtering, clarifying and aging to obtain the health wine. The health wine prepared by the preparation method disclosed by the invention has good liver-protecting and kidney-tonifying effects.